Hatteras Venture Partners

Hatteras Venture Partners is a venture capital and private equity firm specializing in buyouts, pre-seed, seed/startup, early stage, emerging growth, growth capital, and mid venture stages. The firm is an SBIC. It typically invests in life sciences and healthcare companies with a focus on biopharmaceuticals, medical devices, medical device research and development, diagnostics, healthcare IT and health related technologies, and services opportunities in human medicine and health. The firm primarily invests in companies located in the research-driven and capitally-underserved regions of Mid Atlantic such as North Carolina and the Southeastern United States. It seeks to invest between $0.5 million and $4 million initially; and between $5 million and $20 million in total.

TypeInvestor
HQDurham, NC, US
Founded2000
Size (employees)23 (est)
Websitehatterasvp.com
Cybersecurity ratingAMore
Hatteras Venture Partners was founded in 2000 and is headquartered in Durham, NC, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Hatteras Venture Partners

Myla Lai-Goldman

Myla Lai-Goldman

Venture Partner
Christy Shaffer

Christy Shaffer

General Partner
Jeff Terrell

Jeff Terrell

Partner
Ben Scruggs

Ben Scruggs

Principal
Show more

Hatteras Venture Partners Office Locations

Hatteras Venture Partners has an office in Durham
Durham, NC, US (HQ)
280 S Mangum St #350
Show all (1)

Hatteras Venture Partners Online and Social Media Presence

Embed Graph

Hatteras Venture Partners Blogs

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

First Indication for Lead TREM2 Agonist Program Announced as Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Financing Led by Vida Ventures; Stefan Vitorovic, Co-founder and Managing Director, to Join Board of Directors Cambridge, Mass., August 18, 2021—Vigil Neurosci…

Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members

FREDERICK, Md., June 16, 2021 /PRNewswire/ — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the closing of a $16.6 million Series A financing. …

Business North Carolina’s Power List 2021

Congratulations to our esteemed Hatteras Venture Partners colleague Bob Ingram on his recognition for the Business NC Power List for Finance and Insurance 2021. https://businessnc.com/power-list-2021/finance-insurance/

CROs dMed and Clinipace Merge to Accelerate Customer Success

The combined Company will provide full-service CRO services to meet needs of global fast-moving biotech, pharma and medical device companies, and to accelerate the delivery of innovative solutions to patients worldwide. SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ — dMed Global, a ful…

Researchers Look for Ways to Make Drug Trials More Diverse

Technology platforms let researchers draw on participants of various races, ages and locations Pharmaceutical researchers are turning to technology to broaden access to experimental treatments, and make clinical trials more equitable in terms of their inclusion of minorities Minorities are often und…

FDA approves G1 Therapeutics’ COSELA™ (TRILACICLIB): The first and only myeloprotection therapy to decrease the incidence of chemotherapy-induced myelosuppression

– COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy – – Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutrope…
Show more

Hatteras Venture Partners Frequently Asked Questions

  • When was Hatteras Venture Partners founded?

    Hatteras Venture Partners was founded in 2000.

  • Who are Hatteras Venture Partners key executives?

    Hatteras Venture Partners's key executives are Myla Lai-Goldman, Christy Shaffer and Jeff Terrell.

  • How many employees does Hatteras Venture Partners have?

    Hatteras Venture Partners has 23 employees.

  • Where is Hatteras Venture Partners headquarters?

    Hatteras Venture Partners headquarters is located at 280 S Mangum St #350, Durham.

  • Where are Hatteras Venture Partners offices?

    Hatteras Venture Partners has an office in Durham.

  • How many offices does Hatteras Venture Partners have?

    Hatteras Venture Partners has 1 office.